Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenshen Bugu Fang is a Traditional Chinese Medicine (TCM) herbal decoction composed of 16 botanical ingredients, including Astragalus, Codonopsis, and Epimedium. It is primarily investigated for the management of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in postmenopausal women with breast cancer. The formula is designed to "warm the kidney and strengthen the bone" (Wenshen Bugu) according to TCM principles, aiming to alleviate joint pain, stiffness, and bone loss associated with estrogen-depriving endocrine therapies. In clinical research, it is often evaluated as an oral solution administered twice daily, sometimes in combination with complementary therapies like acupoint thread embedding (ATE).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenshen Bugu Fang.